Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) announced a non-dilutive royalty financing agreement with a secured lender, securing $5 million for future royalties on Mytesi (crofelemer) sales. This funding will support regulatory activities, including a pivotal clinical trial for cancer therapy-related diarrhea (CTD), expected to commence in Q4 2020. The agreement may allow for additional financing up to $16 million by July 2021. CEO Lisa Conte emphasized that this option will not dilute shareholder equity and is based on the growing sales of Mytesi for HIV-related diarrhea.
Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, is sponsoring the National Trans Visibility March (NTVM) starting September 28, 2020. In conjunction with this event, Napo will host a virtual workshop on the gastrointestinal (GI) consequences of HIV on September 30, 2020, led by advocate Marissa Miller. Jaguar focuses on plant-based, non-opioid medicines for GI distress, with its product Mytesi approved for treating noninfectious diarrhea in HIV/AIDS patients. The company emphasizes its commitment to health equity and support for marginalized communities.
Jaguar Health (NASDAQ:JAGX) will host its inaugural Diarrhea Dialogues virtual event on October 20, 2020, from 3:00 PM to 4:30 PM EDT. The event focuses on supportive care for cancer patients, specifically addressing debilitating diarrhea caused by cancer therapies. Esteemed oncologists, patient advocates, and Jaguar executives will participate, discussing the significant impact of diarrhea on treatment and quality of life. Additionally, Napo Pharmaceuticals, a subsidiary of Jaguar, is advancing research on Mytesi (crofelemer) for the relief of therapy-related diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 3:00 PM ET. Founder and CEO Lisa Conte will lead the presentation, which focuses on the company's innovative, plant-based pharmaceuticals for gastrointestinal distress. Institutional investors can register for the conference here to arrange one-on-one meetings with Jaguar.
Jaguar's Mytesi (crofelemer) is FDA-approved for noninfectious diarrhea relief in adults with HIV/AIDS.
Jaguar Health, Inc. (JAGX) announced a third amendment to its accounts receivable purchase agreement with Oasis Capital, LLC, allowing Oasis to purchase an additional $2,329,662.72 in accounts receivable related to the sales of Mytesi drug product. This financing aims to enhance the company's cash flow without diluting shareholder equity.
The agreement entails a purchase price of $990,106.65 and a transaction fee of $5,000. This follows the success of previous tranches and indicates Jaguar's commitment to a stable cash flow positive business strategy.
Jaguar Health, Inc. (JAGX) announced on September 2, 2020, it has completed transactions boosting its stockholders' equity above $5 million, meeting the Nasdaq Capital Market's initial listing requirement. Previously, the company reported $1,544,000 in equity at the end of June 2020. The transactions involved exchanging shares of preferred stock and issuing common stock, completed on September 1, 2020. These efforts aim to address a prior notification from Nasdaq regarding a breach of listing rules due to insufficient equity.
Jaguar Health, Inc. (NASDAQ:JAGX) provided updates on its investigator-initiated trials of crofelemer (Mytesi), a plant-based FDA-approved medication. Trials include: 1) Chronic Idiopathic Diarrhea, with full enrollment expected by 2020 year-end and results by mid-2021; 2) Functional Diarrhea, starting enrollment in Q4 2020 with results also anticipated in Q4 2021; and 3) Diarrhea in HER2-positive breast cancer patients, nearing enrollment completion with results due mid-2021. Mytesi uniquely treats noninfectious diarrhea in HIV/AIDS patients and aims to address significant healthcare costs associated with chronic diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) has submitted the final technical section required by the FDA to seek approval for its oral plant-based drug, Canalevia, aimed at treating chemotherapy-induced diarrhea in dogs. With over 50,000 dogs affected annually, Canalevia would be the first FDA-approved medicine for this condition. The company anticipates conditional approval for both chemotherapy-induced and exercise-induced diarrhea by mid-2021. Jaguar’s subsidiary, Napo Pharmaceuticals, markets Mytesi, another crofelemer-based product for humans.
Jaguar Health (NASDAQ:JAGX) has submitted the final technical section to the FDA for approval of Canalevia, a plant-based drug to treat chemotherapy-induced diarrhea (CID) in dogs. This submission marks a significant step towards potentially becoming the first FDA-approved treatment for over 50,000 affected dogs annually. The filing supports conditional approval under the Minor Use/Minor Species Act. Jaguar also plans to seek approval for treating exercise-induced diarrhea. Canalevia aims to improve comfort and chemotherapy tolerance in dogs.
Jaguar Health (NASDAQ:JAGX) announced an amendment to its accounts receivable purchase agreement with Oasis Capital, LLC. This agreement involves the purchase of additional accounts receivable worth $3,152,545 related to Mytesi drug sales. Oasis will pay $1,339,831.83, with a fee of 5.45% on the total amount. The company aims to secure non-dilutive capital to enhance its cash flow. Mytesi is approved for treating noninfectious diarrhea in HIV/AIDS patients.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
